Prothena Presents New Preclinical Data Supporting Best-in-Cl

Prothena Corporation plc , a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced new preclinical data from its PRX012 program, a potential...

Related Keywords

Sweden , Gothenburg , Vastra Gotalands Lan , Wagner Zago , Exchange Commission , Product Service , Nasdaq , Forum Discussions , Company On Twitter Prothenacorp , International Conference On Alzheimer , Prothena Corporation , Next Generation Anti Amyloid Beta Antibody , Plasmon Resonance , Chief Scientific Officer , Prothena Activities , Disease Modifying Treatments , Taking Stock , Two Forum Discussions , From Basics , Anti Tau Therapies , Clinical Trials , Annual Report ,